Literature DB >> 12818621

Poxviruses as vaccine vectors.

P-P Pastoret1, A Vanderplasschen.   

Abstract

The discovery of Jenner in 1798 founded the science of immunology and eventually led to smallpox eradication from the earth in 1980 after a world-wide vaccination campaign with vaccinia virus (another poxvirus) and paradoxically, despite the eradication of smallpox, there has been an explosion of interest in vaccinia virus in the eighties. This interest has stemmed in part from the application of molecular genetics to clone and express foreign genes from recombinant vaccinia viruses. Vaccinia is also gaining renewed interest due to bioterrorism. These recombinant viruses have multiple applications in research and vaccinology and led to the development of vectored vaccines, such as the recombinant vaccinia rabies vaccine used to eliminate rabies in Western Europe and, more recently, in the United States. Secondly, alternative poxvirus vectors, such as avipox viruses, were proved to be even safer and efficacious non-replicating vectors (suiciole vectors) when used in non-avian species.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818621     DOI: 10.1016/S0147-9571(03)00019-5

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  19 in total

Review 1.  Viral vector-based therapeutic cancer vaccines.

Authors:  Cecilia Larocca; Jeffrey Schlom
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats.

Authors:  Kemal Karaca; David E Swayne; Deborah Grosenbaugh; Michel Bublot; Amy Robles; Erica Spackman; Robert Nordgren
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

3.  Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.

Authors:  Fatema A Legrand; Paulo H Verardi; Kenneth S Chan; Yue Peng; Leslie A Jones; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205

Review 4.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

Review 5.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

Review 6.  Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Authors:  Houda Boukhebza; Nadine Bellon; Jean Marc Limacher; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

7.  The Microbial Rosetta Stone Database: a compilation of global and emerging infectious microorganisms and bioterrorist threat agents.

Authors:  David J Ecker; Rangarajan Sampath; Paul Willett; Jacqueline R Wyatt; Vivek Samant; Christian Massire; Thomas A Hall; Kumar Hari; John A McNeil; Cornelia Büchen-Osmond; Bruce Budowle
Journal:  BMC Microbiol       Date:  2005-04-25       Impact factor: 3.605

8.  Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection.

Authors:  Sameera Vipat; Greg Brennan; Chorong Park; Sherry L Haller; Stefan Rothenburg
Journal:  J Vis Exp       Date:  2020-05-24       Impact factor: 1.355

Review 9.  Viral gene therapy.

Authors:  P Mancheño-Corvo; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2006-12       Impact factor: 3.340

10.  Viral and nonviral delivery systems for gene delivery.

Authors:  Nouri Nayerossadat; Talebi Maedeh; Palizban Abas Ali
Journal:  Adv Biomed Res       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.